TABLE 2.
Baseline Demographic and Clinical Characteristics in the 3 Months Before Index Date
| Before parity | After parity | |||
|---|---|---|---|---|
| FIHPs (n = 480) | SFHPs (n = 688) | FIHPs (n = 198) | SFHPs (n = 521) | |
| Age, mean (SD) | 48.3 (10.3) | 49.0 (11.6) | 47.5 (11.7) | 47.8 (11.2) |
| Sex, n (%) | ||||
| Male | 257 (53.5) | 386 (56.1) | 98 (49.5) | 290 (55.6) |
| Female | 223 (46.5) | 302 (43.9) | 100 (50.5) | 231 (44.3) |
| Geographic region, n (%) | ||||
| Northeast | 66 (13.8) | 95 (13.8) | 41 (20.7) | 114 (21.9) |
| North Central | 133 (27.7) | 119 (17.3) | 40 (20.2) | 102 (19.6) |
| South | 193 (40.2) | 287 (41.7) | 98 (49.5) | 207 (39.7) |
| West | 88 (18.3) | 187 (27.2) | 19 (9.6) | 98 (18.8) |
| Health plan type, n (%) | ||||
| Comprehensive | 4 (0.8) | 23 (3.3) | 0 (0) | 16 (3.1) |
| EPO/PPO | 349 (72.7) | 384 (55.8) | 140 (70.7) | 333 (63.9) |
| HMO | 69 (14.4) | 147 (21.4) | 23 (11.6) | 34 (6.5) |
| POS/POS with capitation | 30 (6.3) | 81 (11.8) | 28 (14.1) | 37 (7.1) |
| CDHP/HDHP | 28 (5.8) | 53 (7.7) | 7 (3.5) | 101 (19.4) |
| Number of IP visits, mean (SD) | 1.1 (3.0) | 1.1 (3.0) | 1.0 (3.2) | 1.1 (3.0) |
| Number of OP visits, mean (SD) | 6.5 (4.8) | 7.4 (5.9) | 7.0 (4.8) | 7.2 (5.3) |
| Overall number of medications, mean (SD) | 6.1 (7.2) | 6.3 (6.7) | 6.5 (7.5) | 5.9 (6.4) |
| Weighted Elixhauser score, mean (SD) | 2.4 (5.4) | 2.1 (4.6) | 2.5 (5.7) | 2.4 (5.0) |
| Index treatment agent, n (%) | ||||
| Bosutinib | 2 (0.4) | 0 (0) | 1 (0.5) | 4 (0.8) |
| Dasatinib | 78 (16.3) | 114 (16.6) | 79 (39.9) | 215 (41.3) |
| Imatinib mesylate | 348 (72.5) | 501 (72.8) | 80 (40.4) | 201 (38.6) |
| Nilotinib hydrochloride | 52 (10.8) | 72 (10.5) | 37 (18.7) | 100 (19.2) |
| Ponatinib hydrochloride | 0 (0) | 1 (0.2) | 1 (0.5) | 1 (0.2) |
| Year of index treatment, n (%) | ||||
| 2007 | 36 (7.5) | 66 (9.6) | 0 (0) | 0 (0) |
| 2008 | 70 (14.6) | 88 (12.8) | 1 (0.5) | 0 (0) |
| 2009 | 96 (20.0) | 125 (18.2) | 0 (0) | 2 (0.4) |
| 2010 | 85 (17.7) | 84 (12.2) | 3 (1.5) | 0 (0) |
| 2011 | 70 (14.6) | 105 (15.3) | 8 (4.0) | 9 (1.7) |
| 2012 | 49 (10.2) | 68 (9.9) | 26 (13.1) | 40 (7.7) |
| 2013 | 41 (8.5) | 96 (14.0) | 35 (17.7) | 74 (14.2) |
| 2014 | 28 (5.8) | 46 (6.7) | 41 (20.7) | 65 (12.5) |
| 2015 | 5 (1.0) | 7 (1.0) | 37 (18.7) | 97 (18.6) |
| 2016 | 0 (0) | 3 (0.4) | 39 (19.7) | 158 (30.3) |
| 2017 | 0 (0) | 0 (0) | 8 (4.0) | 76 (14.6) |
| Residing in state specifying limit on OOP spending as component of parity, n (%) | ||||
| No | 276 (57.5) | 338 (49.1) | 145 (73.2) | 411 (78.9) |
| Yes | 204 (42.5) | 350 (50.9) | 53 (26.8) | 110 (21.1) |
CDHP = consumer-driven health plan; EPO = exclusive provider organization; FIHP = fully insured health plan; HDHP = high-deductible health plan; IP = inpatient; OOP = out-of-pocket; OP = outpatient; POS = point-of-service; PPO = preferred provider organization; SFHP = self-funded health plan.